Fonseca Annabelle L, Cha Charles H
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut.
J Surg Oncol. 2014 Nov;110(6):712-9. doi: 10.1002/jso.23673. Epub 2014 Jun 4.
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with a rising incidence in the United States. The increase in medical and locally ablative therapies have improved prognosis, however surgery, either liver resection or transplantation, remains the mainstay of therapy. An increased understanding of liver anatomy, improved imaging modalities and refinements of surgical technique have all led to improved outcomes after surgery. Both resection and transplantation may be used in a complementary manner. Resection remains the treatment of choice for HCC when feasible. Liver transplantation, which removes both the tumor and the underlying diseased liver offers excellent outcomes in patients that meet the Milan criteria. While both these modalities have relatively well defined roles, the treatment of these patients must be tailored individually, using a multidisciplinary approach, to maximize survival, quality of life and allocation of scarce organs.
肝细胞癌(HCC)是全球最常见的恶性肿瘤之一,在美国其发病率呈上升趋势。医学治疗和局部消融治疗的进展改善了预后,然而,手术(肝切除或肝移植)仍然是主要的治疗方法。对肝脏解剖结构的深入了解、成像方式的改进以及手术技术的完善都使得手术后的效果得到了改善。肝切除和肝移植可以互补使用。在可行的情况下,肝切除仍然是HCC的首选治疗方法。肝移植既能切除肿瘤,又能去除潜在的病变肝脏,对于符合米兰标准的患者能带来极佳的治疗效果。虽然这两种治疗方式的作用相对明确,但必须采用多学科方法,根据患者个体情况制定治疗方案,以最大限度地提高生存率、生活质量并合理分配稀缺器官。